NCT02484391View on ClinicalTrials.gov

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

October 31, 2018

Study Completion Date

February 2, 2022

Conditions
Granulocytic SarcomaRecurrent Adult Acute Myeloid Leukemia
Interventions
DRUG

6,8-Bis(benzylthio)octanoic Acid

Given IV

DRUG

Cytarabine

Given IV

PROCEDURE

Hematopoietic Cell Transplantation

Undergo stem cell transplant

DRUG

Mitoxantrone Hydrochloride

Given IV

Trial Locations (1)

27157

Comprehensive Cancer Center of Wake Forest University, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT02484391 - CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma | Biotech Hunter | Biotech Hunter